Yonsei University Clinical Investigator Discusses Results of Opdivo Trial to Address Esophageal Cancer

Yonsei University Clinical Investigator Discusses Results of Opdivo Trial to Address Esophageal Cancer

Esophageal patients have had little option other than chemotherapy for a long time.  Could immunotherapies change that? First Keytruda was approved to treat PD-L1 positive advanced squamous cell esophageal cancer and recently Opdivo (nivolumab) evidenced therapeutic...

Pin It on Pinterest